Vimarsana
Biggest News Aggregation in the World

Page 2 - Interim Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interim Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interim Data Today - Breaking & Trending Today

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection - Vimarsana News

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...

Roche reports inadvertent disclosure in lung cancer immunotherapy study - Vimarsana News

Roche reports inadvertent disclosure in lung cancer immunotherapy study

BERLIN (Reuters) -Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The read-out is not yet statistically significant, meaning that random effects cannot be ruled out with enough certainty, but a Roche spokesperso...

Source: yahoo.com
AstraZeneca CEO says lung cancer drug trial data 'very encouraging' - Vimarsana News

AstraZeneca CEO says lung cancer drug trial data 'very encouraging'

LONDON (Reuters) -AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly resul...

Source: yahoo.com
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress - Vimarsana News

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Omeros Corporation today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association Congress in Frankfurt, Germany are now... | June 12, 2023

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress - Vimarsana News

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation – ... | June 1, 2023